Last reviewed · How we verify

Fujifilm Kyowa Kirin Biologics Co., Ltd. — Portfolio Competitive Intelligence Brief

Fujifilm Kyowa Kirin Biologics Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
FKB327 FKB327 phase 3 Bispecific checkpoint inhibitor PD-L1 and CEACAM1 (TIM-3 ligand) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Akeso · 1 shared drug class
  2. Bio-Thera Solutions · 1 shared drug class
  3. Innovent Biologics (Suzhou) Co. Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fujifilm Kyowa Kirin Biologics Co., Ltd.:

Cite this brief

Drug Landscape (2026). Fujifilm Kyowa Kirin Biologics Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fujifilm-kyowa-kirin-biologics-co-ltd. Accessed 2026-05-17.

Related